Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness - Trial NCT06264700
Access comprehensive clinical trial information for NCT06264700 through Pure Global AI's free database. This phase not specified trial is sponsored by Nationwide Children's Hospital and is currently Not yet recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Nationwide Children's Hospital
Timeline & Enrollment
N/A
Mar 01, 2024
Dec 01, 2025
Primary Outcome
Retention Rate,Sustained Engagement,Electronic Adherence
Summary
This study is for caregivers of young children with sickle cell disease and adolescents with
 sickle cell disease who are currently prescribed hydroxyurea and are receiving care at one of
 the study sites. The study will assess retention and engagement during a pilot randomized
 control trial comparing video directly observed therapy (VDOT) to attention control. We also
 hope to understand more about patient and family preferences longer-term adherence monitoring
 and intervention.
 
 Participants will use an electronic adherence monitor (provided by the study team) to measure
 how often they are taking their hydroxyurea. Participants will also be asked to complete
 questionnaires throughout the study period to provide information about their expectations
 for, experience with, and satisfaction with the study materials.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06264700
Non-Device Trial